1. Home
  2. APLM vs PT Comparison

APLM vs PT Comparison

Compare APLM & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • PT
  • Stock Information
  • Founded
  • APLM 2016
  • PT 2012
  • Country
  • APLM United States
  • PT China
  • Employees
  • APLM N/A
  • PT N/A
  • Industry
  • APLM Blank Checks
  • PT Computer Software: Programming Data Processing
  • Sector
  • APLM Finance
  • PT Technology
  • Exchange
  • APLM Nasdaq
  • PT Nasdaq
  • Market Cap
  • APLM 15.6M
  • PT 14.8M
  • IPO Year
  • APLM N/A
  • PT 2018
  • Fundamental
  • Price
  • APLM $9.75
  • PT $0.94
  • Analyst Decision
  • APLM Strong Buy
  • PT
  • Analyst Count
  • APLM 2
  • PT 0
  • Target Price
  • APLM $425.00
  • PT N/A
  • AVG Volume (30 Days)
  • APLM 102.2K
  • PT 26.5K
  • Earning Date
  • APLM 02-15-2025
  • PT 12-30-2024
  • Dividend Yield
  • APLM N/A
  • PT N/A
  • EPS Growth
  • APLM N/A
  • PT N/A
  • EPS
  • APLM N/A
  • PT N/A
  • Revenue
  • APLM $2,101,000.00
  • PT $4,479,352.00
  • Revenue This Year
  • APLM N/A
  • PT N/A
  • Revenue Next Year
  • APLM N/A
  • PT N/A
  • P/E Ratio
  • APLM N/A
  • PT N/A
  • Revenue Growth
  • APLM 70.54
  • PT N/A
  • 52 Week Low
  • APLM $6.50
  • PT $0.71
  • 52 Week High
  • APLM $105.00
  • PT $1.27
  • Technical
  • Relative Strength Index (RSI)
  • APLM 50.39
  • PT 49.80
  • Support Level
  • APLM $7.23
  • PT $0.90
  • Resistance Level
  • APLM $8.88
  • PT $0.98
  • Average True Range (ATR)
  • APLM 1.37
  • PT 0.07
  • MACD
  • APLM 0.21
  • PT -0.00
  • Stochastic Oscillator
  • APLM 57.91
  • PT 44.44

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees also by providing financing for these borrowers and earn installment service fees, They earn wealth management services fees and commission on financial products.

Share on Social Networks: